IMMUNOREGULATORY DEFECTS IN INFLAMMATORY BOWEL DISEASE

炎症性肠病的免疫调节缺陷

基本信息

项目摘要

Studies of inflammatory bowel disease (IBD) suggest that the basic abnormality consists of an unrestrained immunologic response, not to novel antigen, but rather to common antigens to which the mucosal system is ordinarily unresponsive. To gather data relevant to this hypothesis we have performed extensive studies of control lamina propria T cells. In initial studies we established that as compared to control peripheral blood T cells, lamina propria T cells manifest a greatly reduced response to stimulation via the TCR/CD3 pathway. This was true when cells were studied as a relatively unpurified form or when examined as highly purified CD4+ T cells. Responses via alternative pathways, i.e., via CD2 +/- CD28 were also reduced, but not nearly so reduced as via TCR/CD3. In addition, the unresponsive state could be at least partially reversed by cultured cells in IL-2 alone (not IL-2 plus proliferative stimulus) for 24 hours; this suggested that the unresponsiveness was a form of reversible anergy. Tn further studies, we examined the capacity of peripheral blood and lamina propria T cells to produce various cytokines under the above stimulation conditions. Here we found that both peripheral blood and lamina propria T cells produced relatively low amount of IL-2, as well as IFN-gamma or Il-4, when stimulated via the TCR/CD3 pathway alone, but produced large amounts when stimulated via the CD2/CD28 co-stimulatory pathway. Thus, despite the fact that lamina propria T cells manifest greatly reduced proliferation, they produce as much or more cytokines, as compared to peripheral blood T cells. Finally, we performed studies to elucidate the mechanism of this form of "split" unresponsiveness. In particular, we cross-linked TCR/CD3 T cells under stringent conditions and did indeed induce T cell unresponsiveness (to subsequent stimulation via the TCR/CD3 pathway). However, such cells were also no longer responsive via the CD2 pathway either by proliferation or cytokine production. Thus, the unresponsiveness/responsiveness of lamina propria cells cannot yet be reproduced in culture. Overall, these studies reveal that lamina propria T cells achieve a unique functional state which allows them to act as effector cells in the local mucosal environment.
炎症性肠病(IBD)的研究表明, 异常包括不受限制的免疫反应,而不是新的 抗原,而是针对粘膜系统所针对的共同抗原。 通常没有反应。 为了收集与这一假设相关的数据, 对对照固有层T细胞进行了广泛的研究。 在 初步研究我们确定,与对照外周血相比, 血液T细胞,固有层T细胞表现出大大降低的反应 通过TCR/CD 3途径刺激。 这是真的当细胞 作为相对未纯化的形式进行研究,或者当作为高度纯化的形式进行检查时, 纯化的CD 4 + T细胞。 通过替代途径的反应,即,通过CD 2 +/-CD 28也减少,但不像通过TCR/CD 3那样减少。 在 此外,无响应状态可以通过以下方式至少部分地逆转: 在单独的IL-2(不是IL-2加增殖刺激物)中培养细胞24 小时;这表明无反应是一种可逆的形式, 无反应 在进一步的研究中,我们检测了外周血容量, 和固有层T细胞,以在上述条件下产生各种细胞因子 刺激条件 我们发现外周血和 固有层T细胞产生相对低量的IL-2,以及 IFN-γ或IL-4,当单独通过TCR/CD 3途径刺激时,但 当通过CD 2/CD 28共刺激因子刺激时, 通路因此,尽管固有层T细胞表现出 大大减少增殖,它们产生尽可能多或更多的细胞因子, 与外周血T细胞相比。 最后,我们进行了研究, 阐明这种形式的“分裂”无反应的机制。 在 特别地,我们在严格条件下交联TCR/CD 3 T细胞, 确实诱导T细胞无反应性(通过 TCR/CD 3途径)。 然而,这样的细胞也不再响应 通过CD 2途径通过增殖或细胞因子产生。 因此,在本发明中, 固有层细胞的无反应性/反应性还不能 在文化中复制。 总的来说,这些研究表明, T细胞达到一种独特的功能状态,使它们能够充当 局部粘膜环境中的效应细胞。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

W STROBER其他文献

W STROBER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('W STROBER', 18)}}的其他基金

REGULATION OF IMMUNE RESPONSES IN HUMANS AND NON-HUMAN PRIMATES
人类和非人类灵长类动物免疫反应的调节
  • 批准号:
    3768794
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STUDIES OF PRIMARY IMMUNODEFICIENCY DISEASES
原发性免疫缺陷疾病的研究
  • 批准号:
    3746594
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
IMMUNOREGULATORY DEFECTS IN INFLAMMATORY BOWEL DISEASE
炎症性肠病的免疫调节缺陷
  • 批准号:
    3790738
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
REGULATION OF MUCOSAL IMMUNE RESPONSES IN HUMANS AND NON-HUMAN PRIMATES
人类和非人类灵长类动物粘膜免疫反应的调节
  • 批准号:
    3790755
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
REGULATION OF IMMUNE RESPONSES IN HUMANS AND NON-HUMAN PRIMATES
人类和非人类灵长类动物免疫反应的调节
  • 批准号:
    2566773
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STUDIES OF PRIMARY IMMUNODEFICIENCY DISEASES
原发性免疫缺陷疾病的研究
  • 批准号:
    5200518
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
REGULATION OF IMMUNE RESPONSES IN HUMANS AND NON-HUMAN PRIMATES
人类和非人类灵长类动物免疫反应的调节
  • 批准号:
    5200470
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
IMMUNOREGULATORY DEFECTS IN INFLAMMATORY BOWEL DISEASE
炎症性肠病的免疫调节缺陷
  • 批准号:
    5200452
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STUDIES OF PRIMARY IMMUNODEFICIENCY DISEASES
原发性免疫缺陷疾病的研究
  • 批准号:
    3768849
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
IMMUNOREGULATORY DEFECTS IN INFLAMMATORY BOWEL DISEASE
炎症性肠病的免疫调节缺陷
  • 批准号:
    3768779
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10581488
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574979-2022
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10332251
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574984-2022
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574985-2022
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574978-2022
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
  • 批准号:
    444149
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
  • 批准号:
    RGPIN-2015-05491
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了